Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases

International Journal of Colorectal Disease

Volumn 18, Issue 2, 2003, Pages 142-147

  Ludwiczek, O ^a   Kaser, A ^a   Tilg, Herbert ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Crohn's disease; Cytokines; Inflammatory bowel disease; sCD40 ligand; Ulcerative colitis

Indexed keywords

ALPHA1 GLYCOPROTEIN; AMINOSALICYLIC ACID; AZATHIOPRINE; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; STEROID;

ABSCESS; ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE MARKER; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; INTESTINE FISTULA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SCORING SYSTEM; T LYMPHOCYTE; ULCERATIVE COLITIS; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; CD40 LIGAND; COLITIS, ULCERATIVE; CROHN DISEASE; DIARRHEA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED;

EID: 0038390440     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-002-0425-4     Document Type: Article

References (44)

1. Podolsky DK (1991) Inflammatory bowel disease. I. N Engl J Med 325:928-937
2. MacDermott RP (1994) Alterations in the mucosal immune system in ulcerative colitis and Crohn's disease. Med Clin North Am 78:1207-1231
3. Van Kemseke C, Belaiche J, Louis E (2000) Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis 15:206-210
4. Sartor RB (1997) Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92:5S-11S
5. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182-205
6. Wirtz S, Neurath MF (2000) Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int J Colorectal Dis 15:144-160
7. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:1261-1270
8. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S (1997) Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 150:823-832
9. Powrie F (1995) T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 3:171-174
10. Pospai D, Rene E, Fiasse R, Farahat K, Beaugery L, Lammens P, Reimund C, Duclos B, Le Quintrec Y, Vandercam B, Mignon M (1998) Crohn's disease stable remission after human immunodeficiency virus infection. Dig Dis Sci 43:412-419
11. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12:881-922
12. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ (1996) Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 14:591-617
13. Kooten C van, Banchereau J (1997) Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 9:330-337
14. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK (1993) CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178:669-674
15. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D (1995) Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 155:4917-4925
16. Shu U, Kiniwa M, Wu CY, Maliszewski C, Vezzio N, Hakimi J, Gately M, Delespesse G (1995) Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 25:1125-1128
17. Kennedy MK, Picha KS, Fanslow WC, Grabstein KH, Alderson MR, Clifford KN, Chin WA, Mohler KM (1996) CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur J Immunol 26:370-378
18. Caux C, Massacrier C, Vanbervliet B, Dubois B, van Kooten C, Durand I, Banchereau J (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263-1272
19. Grewal Is, Flavell RA (1998) CD40 and CD 154 in cell-mediated immunity. Annu Rev Immunol 16:111-135
20. Grewal IS, Flavell RA (1996) A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 17:410-414
21. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063-2073
22. Koshy M, Berger D, Crow MK (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98:826-837
23. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 93:2499-2504
24. Faure GC, Bensoussan-Lejzerowicz D, Bene MC, Aubert V, Leclere J (1997) Coexpression of CD40 and class II antigen HLA-DR in Graves' disease thyroid epithelial cells. Clin Immunol Immunopathol 84:212-215
25. Battaglia E, Biancone L, Resegotti A, Emanuelli G, Fronda GR, Camussi G (1999) Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am J Gastroenterol 94:3279-3284
26. Polese L, Angriman I, Cecchetto A, Norberto L, Scarpa M, Ruffolo C, Barollo M, Sommariva A, D'Amico DF (2002) The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol 14:237-241
27. Liu Z, Colpaert S, D'Haens GR, Kasran A, de Boer M, Rutgeerts P, Geboes K, Ceuppens JL (1999) Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 163:4049-4057
28. Clegg CH, Rulffes JT, Haugen HS, Hoggatt IH, Aruffo A, Durham SK, Farr AG, Hollenbaugh D (1997) Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int Immunol 9:1111-1122
29. Stuber E, Strober W, Neurath M (1996) Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med 183:693-698
30. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, Gauchat JF, Bernard A, Allet B, Bonnefoy JY (1995) Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 270:7025-7028
31. Ludewig B, Henn V, Schroder JM, Graf D, Kroczek RA (1996) Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells With dendritic cells. Eur J Immunol 26:3137-3143
32. Notarangelo LD, Peitsch MC (1996) CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Today 17:511-516
33. Finck BK, Linsley PS, Wofsy D (1994) Treatment of murine lupus with CTLA4Ig. Science 265:1225-1227
34. Mohan C, Shi Y, Laman JD, Datta SK (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 154:1470-1480
35. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ (1993) Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261:1328-1330
36. Howard LM, Miga AJ, Vanderlugt CL, Dal Canto MC, Laman JD, Noelle RJ, Miller SD (1999) Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 103:281-290
37. Carayanniotis G, Masters SR, Noelle RJ (1997) Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 90:421-426
38. Im SH, Barchan D, Maiti PK, Fuchs S, Souroujon MC (2001) Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol 166:6893-6898
39. Homann D, Jahreis A, Wolfe T, Hughes A, Coon B, van Stipdonk MJ, Prilliman KR, Schoenberger SP, von Herrath MG (2002) CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity 16:403-415
40. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D (2001) Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 28:95-101
41. Sandborn WJ, Targan SR (2002) Biologic therapy of inflammatory bowel disease. Gastroenterology 122:1592-1608
42. Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82-86
43. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405
44. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK (1999) Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 42:871-881